2023 - Research.com Immunology in Poland Leader Award
2022 - Research.com Immunology in Poland Leader Award
His scientific interests lie mostly in Asthma, Immunology, Internal medicine, Allergy and Placebo. He combines subjects such as Quality of life, Allergen immunotherapy, Allergen, Family medicine and Intensive care medicine with his study of Asthma. In his work, Basophil and Immunoglobulin E is strongly intertwined with Histamine, which is a subfield of Immunology.
His Internal medicine study combines topics from a wide range of disciplines, such as Gastroenterology, Endocrinology and Placebo-controlled study. His Allergy research is multidisciplinary, incorporating elements of Visual analogue scale, Quality of life, rhinorrhea and Position paper. His Placebo research incorporates themes from Benralizumab, Anesthesia, Exacerbation, Adverse effect and Reslizumab.
His primary areas of investigation include Asthma, Immunology, Internal medicine, Allergy and Placebo. His Asthma study incorporates themes from Anesthesia, Pediatrics, Family medicine and Intensive care medicine. As part of the same scientific family, Piotr Kuna usually focuses on Family medicine, concentrating on Health care and intersecting with Quality of life.
He has included themes like Peripheral blood mononuclear cell and Histamine in his Immunology study. His Internal medicine research incorporates elements of Gastroenterology and Endocrinology. Allergy is closely attributed to Dermatology in his work.
Piotr Kuna mostly deals with Asthma, Internal medicine, Allergy, Family medicine and Intensive care medicine. His work carried out in the field of Asthma brings together such families of science as mHealth, Integrated care, Health care, Observational study and Disease. His work in the fields of Internal medicine, such as Aspirin, Clinical significance and Adverse effect, overlaps with other areas such as In patient.
Allergy and COPD are commonly linked in his work. He interconnects Psychological intervention, Guideline, MEDLINE and Quality of life in the investigation of issues within Family medicine. His Intensive care medicine research is multidisciplinary, relying on both Benralizumab, Mepolizumab, Multimorbidity, Allergen and Pharmacotherapy.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs
J. Bousquet;H. J. Schünemann;B. Samolinski;P. Demoly.
The Journal of Allergy and Clinical Immunology (2012)
Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)
J. Bousquet;N. Khaltaev;A. A. Cruz;J. Denburg.
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision
Jan L. Brożek;Jean Bousquet;Ioana Agache;Arnav Agarwal.
The Journal of Allergy and Clinical Immunology (2017)
International consensus on (ICON) pediatric asthma
N. G. Papadopoulos;H. Arakawa;A. Custovic;J. Gern.
Sub-Lingual Immunotherapy: World Allergy Organization Position Paper 2009
G Walter Canonica;Jean Bousquet;Thomas Casale;Richard F Lockey.
World Allergy Organization Journal (2009)
Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma.
Parameswaran Nair;Sally Wenzel;Klaus F. Rabe;Arnaud Bourdin.
The New England Journal of Medicine (2017)
Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009.
Canonica Gw;Bousquet J;Casale T;Lockey Rf.
Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy
Allen P Kaplan;Dennis Ledford;Mark Ashby;Janice Canvin.
The Journal of Allergy and Clinical Immunology (2013)
Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study
Mario Castro;Sally E Wenzel;Eugene R Bleecker;Emilio Pizzichini.
The Lancet Respiratory Medicine (2014)
Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial.
Sven-Erik Dahlén;Kerstin Malmström;Ewa Nizankowska;Barbro Dahlén.
American Journal of Respiratory and Critical Care Medicine (2002)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: